Acadia Pharmaceuticals | ACAD - Gross Profit On Sales


Acadia Pharmaceuticals reported $279.64M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
ALKERMES USD 375.31M 43.98M Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 252.09M 90.07M Jun/2026
Cytokinetics USD 23.03M 3.84M Jun/2026
Eisai JPY 183.24B 29.83B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Incyte USD 1.57B 400.89M Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Moderna USD -566M 792M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Pfizer USD -248M 11.29B Jun/2026
Prothena USD 51.08M 51.06M Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026